Periprosthetic joint infection: from biofilm pathophysiology to precision management—a comprehensive clinical review

Periprosthetic joint infection (PJI) is among the most serious complications of total joint arthroplasty, with incidence of approximately 1%–2% after primary procedures and rising absolute numbers driven by aging populations and growing surgical volumes. Its pathophysiological cornerstone is bacterial biofilm formation on implant surfaces, which confers tolerance to antimicrobials and host immunity through extracellular polymeric substance barriers, metabolic dormancy, and persister cells. This narrative review synthesizes evidence across the PJI continuum—epidemiology, risk stratification, biofilm pathophysiology, diagnostics, treatment, and emerging technologies—explicitly stratifying the cited evidence by maturity, from in vitro studies to randomized trials. We review the evolving pathogen spectrum, including methicillin-resistant Staphylococcus aureus and multidrug-resistant gram-negative organisms. Synovial calprotectin, metagenomic next-generation sequencing, and artificial intelligence are appraised alongside conventional culture and serology, with attention to their limitations. Treatment strategies—debridement, antibiotics, and implant retention (DAIR), one-stage and two-stage exchange, and permanent articulating spacers—are discussed in relation to infection chronicity, host status, and pathogen phenotype. Emerging anti-biofilm therapeutics, including monoclonal antibodies, bacteriophages, photothermal nano-agents, and antimicrobial peptides, are categorized by evidence level and translational readiness. Finally, we identify evidence gaps and propose research priorities—standardized biofilm models, multicenter registries, and rigorously designed trials—needed before precision management of PJI can be realized in routine practice.

Authors

Institutions

Publication Details

Journal
Frontiers in Cellular and Infection Microbiology
Published
2026-11-19
DOI
https://doi.org/10.3389/fcimb.2026.1980967
Primary Topic
Orthopedic Infections and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Periprosthetic joint infection: from biofilm pathophysiology to precision management—a comprehensive clinical review

Shuai Zhang, Nan Yang, Jing Wang, Yan Liu et al.
Frontiers in Cellular and Infection Microbiology
Orthopedic Infections and Treatments
article

Periprosthetic joint infection: from biofilm pathophysiology to precision management—a comprehensive clinical review

Shuai Zhang, Nan Yang, Jing Wang, Yan Liu, Qian Zhang, Yalin Zhao, Xinxin Du, Xia Wu, Cong Zhang, Jianxue Yu
article en

Abstract

Periprosthetic joint infection (PJI) is among the most serious complications of total joint arthroplasty, with incidence of approximately 1%–2% after primary procedures and rising absolute numbers driven by aging populations and growing surgical volumes. Its pathophysiological cornerstone is bacterial biofilm formation on implant surfaces, which confers tolerance to antimicrobials and host immunity through extracellular polymeric substance barriers, metabolic dormancy, and persister cells. This narrative review synthesizes evidence across the PJI continuum—epidemiology, risk stratification, biofilm pathophysiology, diagnostics, treatment, and emerging technologies—explicitly stratifying the cited evidence by maturity, from in vitro studies to randomized trials. We review the evolving pathogen spectrum, including methicillin-resistant Staphylococcus aureus and multidrug-resistant gram-negative organisms. Synovial calprotectin, metagenomic next-generation sequencing, and artificial intelligence are appraised alongside conventional culture and serology, with attention to their limitations. Treatment strategies—debridement, antibiotics, and implant retention (DAIR), one-stage and two-stage exchange, and permanent articulating spacers—are discussed in relation to infection chronicity, host status, and pathogen phenotype. Emerging anti-biofilm therapeutics, including monoclonal antibodies, bacteriophages, photothermal nano-agents, and antimicrobial peptides, are categorized by evidence level and translational readiness. Finally, we identify evidence gaps and propose research priorities—standardized biofilm models, multicenter registries, and rigorously designed trials—needed before precision management of PJI can be realized in routine practice.

Frontiers in Cellular and Infection MicrobiologyVol. 16
Hebei Medical University (CN), Third Hospital of Hebei Medical University (CN)
Orthopedic Infections and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon